Paul A Lapchak

List of Publications by Year in Descending Order

139 papers	6,204 citations	41 h-index	74 g-index
144 ext. papers	6,619 ext. citations	5.4 avg, IF	6.04 L-index

#	Paper	IF	Citations
139	The challenge of effectively translating transcranial near-infrared laser therapy to treat acute ischemic stroke **2019**, 289-297		
138	CNB-001 reduces paraplegia in rabbits following spinal cord ischemia. *Neural Regeneration Research* , **2019**, 14, 2192-2198	4.5	3
137	CNB-001, a pleiotropic drug is efficacious in embolized agyrencephalic New Zealand white rabbits and ischemic gyrencephalic cynomolgus monkeys. *Experimental Neurology*, **2019**, 313, 98-108	5.7	5
136	Data Standardization and Quality Management. *Translational Stroke Research*, **2018**, 9, 4-8	7.8	10
135	Translational Stroke Research Guideline Projections: The 20/20 Standards. *Translational Stroke Research*, **2018**, 9, 9-12	7.8	8
134	Intravenous xenogeneic human cardiosphere-derived cell extracellular vesicles (exosomes) improves behavioral function in small-clot embolized rabbits. *Experimental Neurology*, **2018**, 307, 109-117	5.7	21
133	Stroke: Cytoprotection, Repair and Regeneration The Continuum of Patient Care. *Springer Series in Translational Stroke Research*, **2018**, 3-20	0.1	
132	Cytoprotective Drug-Tissue Plasminogen Activator Protease Interaction Assays: Screening of Two Novel Cytoprotective Chromones. *Translational Stroke Research*, **2017**, 8, 494	7.8	2
131	Stroke Cytoprotection: Can Repeating History with New Expectations Really Be the Path to Success in Stroke Research?. *Translational Stroke Research*, **2017**, 8, 104-106	7.8	3
130	The High Cost of Stroke and Stroke Cytoprotection Research. *Translational Stroke Research*, **2017**, 8, 307-317	7.8	56
129	Reflections on Neuroprotection Research and the Path Toward Clinical Success. *Springer Series in Translational Stroke Research*, **2017**, 3-71	0.1	2
128	Rabbit Spinal Cord Ischemia Model for the Development of Neuroprotective Treatments. *Springer Series in Translational Stroke Research*, **2017**, 689-700	0.1	2
127	Stroke Therapy Development Successes: Research Guidelines and Embolic Stroke Models for Monotherapy and Adjuvant Therapy Development. *Translational Medicine Research*, **2017**, 3-27		
126	Transcranial Near-Infrared Laser Therapy for Stroke: How to Recover from Futility in the NEST-3 Clinical Trial. *Acta Neurochirurgica Supplementum*, **2016**, 121, 7-12	1.7	23
125	Chapter 38 Difficult Path to Treating Acute Ischemic Stroke Patients with Transcranial Near-Infrared Laser Therapy **2016**, 741-760		1
124	A novel method to promote behavioral improvement and enhance mitochondrial function following an embolic stroke. *Brain Research*, **2016**, 1646, 125-131	3.7	10
123	A blinded, randomized study of L-arginine in small clot embolized rabbits. *Experimental Neurology*, **2015**, 266, 143-6	5.7	12

122	A cost-effective rabbit embolic stroke bioassay: insight into the development of acute ischemic stroke therapy. *Translational Stroke Research*, **2015**, 6, 99-103	7.8	15
121	Dose-specific effect of simvastatin on hypoxia-induced HIF-1 and BACE expression in Alzheimer's disease cybrid cells. *BMC Neurology*, **2015**, 15, 127	3.1	19
120	Methodology of motor evoked potentials in a rabbit model. *Translational Stroke Research*, **2015**, 6, 399-406	7.8	5
119	Critical early thrombolytic and endovascular reperfusion therapy for acute ischemic stroke victims: a call for adjunct neuroprotection. *Translational Stroke Research*, **2015**, 6, 345-54	7.8	32
118	Neuronal Dysregulation in Stroke-Associated Pseudobulbar Affect (PBA): Diagnostic Scales and Current Treatment Options. *Journal of Neurology & Neurophysiology*, **2015**, 6,	0.5	7
117	Transcranial Near-Infrared Laser Transmission (NILT) Profiles (800 nm): Systematic Comparison in Four Common Research Species. *PLoS ONE*, **2015**, 10, e0127580	3.7	41
116	Novel curcumin derivative CNB-001 mitigates obesity-associated insulin resistance. *Journal of Pharmacology and Experimental Therapeutics*, **2014**, 349, 248-57	4.7	26
115	Effect of the Pleiotropic Drug CNB-001 on Tissue Plasminogen Activator (tPA) Protease Activity in vitro: Support for Combination Therapy to Treat Acute Ischemic Stroke. *Journal of Neurology & Neurophysiology*, **2014**, 5,	0.5	6
114	RIGOR guidelines: escalating STAIR and STEPS for effective translational research. *Translational Stroke Research*, **2013**, 4, 279-85	7.8	175
113	Recommendations for preclinical research in hemorrhagic transformation. *Translational Stroke Research*, **2013**, 4, 322-7	7.8	29
112	Drug-like property profiling of novel neuroprotective compounds to treat acute ischemic stroke: guidelines to develop pleiotropic molecules. *Translational Stroke Research*, **2013**, 4, 328-42	7.8	14
111	Development of transcranial sonothrombolysis as an alternative stroke therapy: incremental scientific advances toward overcoming substantial barriers. *Expert Review of Medical Devices*, **2013**, 10, 201-13	3.5	4
110	Edaravone (Radicut), a free radical scavenger, is a potentially useful addition to thrombolytic therapy in patients with acute ischemic stroke. *Biomedical Reports*, **2013**, 1, 7-12	1.8	31
109	Recommendations and practices to optimize stroke therapy: developing effective translational research programs. *Stroke*, **2013**, 44, 841-3	6.7	32
108	J-147 a Novel Hydrazide Lead Compound to Treat Neurodegeneration: CeeTox Safety and Genotoxicity Analysis. *Journal of Neurology & Neurophysiology*, **2013**, 4,	0.5	1
107	Synergistic Effect of AJW200, a von Willebrand Factor Neutralizing Antibody with Low Dose (0.9 mg/mg) Thrombolytic Therapy Following Embolic Stroke in Rabbits. *Journal of Neurology & Neurophysiology*, **2013**, 4,	0.5	9
106	Transcranial near-infrared laser therapy applied to promote clinical recovery in acute and chronic neurodegenerative diseases. *Expert Review of Medical Devices*, **2012**, 9, 71-83	3.5	43
105	A Clinically Relevant Rabbit Embolic Stroke Model for Acute Ischemic Stroke Therapy Development: Mechanisms and Targets **2012**, 541-584		6

104	Sisyphus and translational stroke research. *Science Translational Medicine*, **2012**, 4, 156ps20	17.5	7
103	A series of novel neuroprotective blood brain barrier penetrating flavonoid drugs to treat acute ischemic stroke. *Current Pharmaceutical Design*, **2012**, 18, 3694-703	3.3	10
102	Scientific Rigor Recommendations for Optimizing the Clinical Applicability of Translational Research. *Journal of Neurology & Neurophysiology*, **2012**, 3,	0.5	16
101	Identifying Vascular Targets to Treat Hemorrhagic Stroke **2012**, 37-55		
100	A novel neuroprotective curcuminoid alleviates glucose intolerance and improves insulin signaling. *FASEB Journal*, **2012**, 26, 672.7	0.9	
99	CeeTox Analysis to De-risk Drug Development: The Three Antioxidants (NXY-059, Radicut, and STAZN) **2012**, 639-656		1
98	Neuroprotective and neurotrophic curcuminoids to treat stroke: a translational perspective. *Expert Opinion on Investigational Drugs*, **2011**, 20, 13-22	5.9	41
97	Delayed treatment with a novel neurotrophic compound reduces behavioral deficits in rabbit ischemic stroke. *Journal of Neurochemistry*, **2011**, 116, 122-31	6	41
96	CeeTox Analysis of CNB-001 a Novel Curcumin-Based Neurotrophic/Neuroprotective Lead Compound to Treat Stroke: Comparison with NXY-059 and Radicut. *Translational Stroke Research*, **2011**, 2, 51-9	7.8	23
95	Resolving the negative data publication dilemma in translational stroke research. *Translational Stroke Research*, **2011**, 2, 1-6	7.8	14
94	De-Risking of Stilbazulenyl Nitrone (STAZN), a Lipophilic Nitrone to Treat Stroke Using a Unique Panel of In Vitro Assays. *Translational Stroke Research*, **2011**, 2, 209-17	7.8	15
93	Continuous monitoring of changes in plasma nitrite following cerebral ischemia in a rabbit embolic stroke model. *Translational Stroke Research*, **2011**, 2, 218-26	7.8	4
92	Emerging Therapies: Pleiotropic Multi-target Drugs to Treat Stroke Victims. *Translational Stroke Research*, **2011**, 2, 129-35	7.8	24
91	Vascular Dysfunction in Brain Hemorrhage: Translational Pathways to Developing New Treatments from Old Targets. *Journal of Neurology & Neurophysiology*, **2011**, 2011,	0.5	9
90	Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma!. *Expert Opinion on Investigational Drugs*, **2010**, 19, 1179-86	5.9	14
89	Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy translational science. *Annals of Medicine*, **2010**, 42, 576-86	1.5	66
88	A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy?. *Expert Opinion on Pharmacotherapy*, **2010**, 11, 1753-63	4	139
87	Transcranial near infrared laser therapy (NILT) to treat acute ischemic stroke: a review of efficacy, safety and possible mechanism of action derived from rabbit embolic stroke studies **2010**,		1

86	Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. *Translational Stroke Research*, **2010**, 1, 96-107	7.8	63
85	Genome response to tissue plasminogen activator in experimental ischemic stroke. *BMC Genomics*, **2010**, 11, 254	4.5	14
84	Transcranial near infrared laser treatment (NILT) increases cortical adenosine-5Ctriphosphate (ATP) content following embolic strokes in rabbits. *Brain Research*, **2010**, 1306, 100-5	3.7	111
83	Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: a combination therapy study with tissue plasminogen activator. *Brain Research*, **2010**, 1309, 136-45	3.7	17
82	Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator. *Brain Research*, **2010**, 1344, 217-25	3.7	20
81	A new embolus injection method to evaluate intracerebral hemorrhage in New Zealand white rabbits. *Brain Research*, **2010**, 1349, 129-36	3.7	5
80	Comparison of the post-embolization effects of tissue-plasminogen activator and simvastatin on neurological outcome in a clinically relevant rat model of acute ischemic stroke. *Brain Research*, **2010**, 1354, 206-16	3.7	13
79	Effect of internal carotid artery reperfusion in combination with Tenecteplase on clinical scores and hemorrhage in a rabbit embolic stroke model. *Brain Research*, **2009**, 1294, 211-7	3.7	13
78	The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits. *Brain Research*, **2009**, 1303, 144-50	3.7	19
77	The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. *Experimental Neurology*, **2009**, 215, 95-100	5.7	38
76	Therapeutic window for nonerythropoietic carbamylated-erythropoietin to improve motor function following multiple infarct ischemic strokes in New Zealand white rabbits. *Brain Research*, **2008**, 1238, 208-14	3.7	32
75	Carbamylated erythropoietin to treat neuronal injury: new development strategies. *Expert Opinion on Investigational Drugs*, **2008**, 17, 1175-86	5.9	27
74	The many faces of erythropoietin: from erythropoiesis to a rational neuroprotective strategy--correspondence. *Expert Opinion on Investigational Drugs*, **2008**, 17, 1615-6	5.9	2
73	Safety profile of transcranial near-infrared laser therapy administered in combination with thrombolytic therapy to embolized rabbits. *Stroke*, **2008**, 39, 3073-8	6.7	55
72	Tumor necrosis factor-alpha is involved in thrombolytic-induced hemorrhage following embolic strokes in rabbits. *Brain Research*, **2007**, 1167, 123-8	3.7	10
71	A novel approach to screening for new neuroprotective compounds for the treatment of stroke. *Brain Research*, **2007**, 1173, 117-25	3.7	104
70	Advances in ischemic stroke treatment: neuroprotective and combination therapies. *Expert Opinion on Emerging Drugs*, **2007**, 12, 97-112	3.7	74
69	Advances in hemorrhagic stroke therapy: conventional and novel approaches. *Expert Opinion on Emerging Drugs*, **2007**, 12, 389-406	3.7	37

68	The phenylpropanoid micronutrient chlorogenic acid improves clinical rating scores in rabbits following multiple infarct ischemic strokes: synergism with tissue plasminogen activator. *Experimental Neurology*, **2007**, 205, 407-13	5.7	40
67	Memantine, an uncompetitive low affinity NMDA open-channel antagonist improves clinical rating scores in a multiple infarct embolic stroke model in rabbits. *Brain Research*, **2006**, 1088, 141-7	3.7	25
66	3alpha-OL-5-beta-pregnan-20-one hemisuccinate, a steroidal low-affinity NMDA receptor antagonist improves clinical rating scores in a rabbit multiple infarct ischemia model: synergism with tissue plasminogen activator. *Experimental Neurology*, **2006**, 197, 531-7	5.7	16
65	Transcranial infrared laser therapy improves clinical rating scores after embolic strokes in rabbits. *Stroke*, **2004**, 35, 1985-8	6.7	161
64	Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits. *Experimental Neurology*, **2004**, 185, 154-9	5.7	56
63	Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. *Experimental Neurology*, **2004**, 188, 279-85	5.7	41
62	Pharmacology of caffeinol in embolized rabbits: clinical rating scores and intracerebral hemorrhage incidence. *Experimental Neurology*, **2004**, 188, 286-91	5.7	19
61	Development of the nitrone-based spin trap agent NXY-059 to treat acute ischemic stroke. *CNS Neuroscience & Therapeutics*, **2003**, 9, 253-62		30
60	Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator. *Stroke*, **2003**, 34, 2013-8	6.7	75
59	Effects of intrathecal administration of a cell permeant caspase inhibitor, boc-D-fluoromethylketone (BDFMK), on behavioral deficits following spinal cord ischemia: a dose-response analysis. *Brain Research*, **2003**, 959, 183-90	3.7	9
58	Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in the management of ischemic stroke. *American Journal of Cardiovascular Drugs*, **2003**, 3, 87-94	4	13
57	Effects of the spin trap agent disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator. *Stroke*, **2002**, 33, 1665-70	6.7	78
56	The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke. *Stroke*, **2002**, 33, 147-52	6.7	37
55	Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment. *Current Neurology and Neuroscience Reports*, **2002**, 2, 38-43	6.6	71
54	Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. *Stroke*, **2002**, 33, 1411-5	6.7	101
53	Development of thrombolytic therapy for stroke: a perspective. *Expert Opinion on Investigational Drugs*, **2002**, 11, 1623-32	5.9	50
52	Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. *Stroke*, **2002**, 33, 2279-84	6.7	93
51	Spin Trap Agents: A New Approach to Stroke Therapy. *Drug News and Perspectives*, **2002**, 15, 220-225		7

50	NXY-059. Centaur. *Current Opinion in Investigational Drugs*, **2002**, 3, 1758-62		5
49	Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6, 6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. *Stroke*, **2001**, 32, 147-53	6.7	57
48	Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. *Stroke*, **2001**, 32, 748-52	6.7	48
47	Neuroprotection by the selective cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioral deficits induced by reversible spinal cord ischemia. *Stroke*, **2001**, 32, 1220-5	6.7	41
46	Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents. *CNS Drugs*, **2001**, 15, 819-29	6.7	31
45	Preclinical development of neurosteroids as neuroprotective agents for the treatment of neurodegenerative diseases. *International Review of Neurobiology*, **2001**, 46, 379-97	4.4	61
44	Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. *Stroke*, **2000**, 31, 3034-40	6.7	293
43	Dehydroepiandrosterone sulfate is neuroprotective in a reversible spinal cord ischemia model: possible involvement of GABA(A) receptors. *Stroke*, **2000**, 31, 1953-6; discussion 1957	6.7	102
42	Glial cell line-derived neurotrophic factor protects midbrain dopamine neurons from the lethal action of the weaver gene: a quantitative immunocytochemical study. *Developmental Brain Research*, **1999**, 116, 1-7		15
41	Characterization of a fibrin glue-GDNF slow-release preparation. *Cell Transplantation*, **1998**, 7, 53-61	4	24
40	Glial cell line-derived neurotrophic factor: a novel therapeutic approach to treat motor dysfunction in Parkinson disease. *Experimental Neurology*, **1997**, 144, 29-34	5.7	38
39	Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats. *Experimental Neurology*, **1997**, 145, 104-17	5.7	50
38	Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson disease. *Experimental Neurology*, **1997**, 145, 309-21	5.7	45
37	Glial cell line-derived neurotrophic factor: distribution and pharmacology in the rat following a bolus intraventricular injection. *Brain Research*, **1997**, 747, 92-102	3.7	78
36	Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson disease. *Brain Research*, **1997**, 777, 153-60	3.7	81
35	Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. *Annals of Neurology*, **1997**, 42, 208-14	9.4	54
34	Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS. *Reviews in the Neurosciences*, **1996**, 7, 165-76	4.7	40
33	Glial cell line-derived neurotrophic factor reverses motor impairment in 16-17 month old rats. *Neuroscience Letters*, **1996**, 211, 81-4	3.3	35

32	Biology of glial cell line-derived neurotrophic factor (GDNF): implications for the use of GDNF to treat Parkinson's disease. *Experimental Neurology*, **1996**, 5, 197-205		35
31	Enhanced delivery of [125I]glial cell line-derived neurotrophic factor to the rat CNS following osmotic blood-brain barrier modification. *Neuroscience Letters*, **1996**, 220, 187-90	3.3	16
30	Pharmacological characterization of glial cell line-derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule for treating neurodegenerative diseases. *Cell and Tissue Research*, **1996**, 286, 179-89	4.2	51
29	Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a Hirschsprung disease patient. *Nature Genetics*, **1996**, 14, 341-4	36.3	252
28	Functional recovery in parkinsonian monkeys treated with GDNF. *Nature*, **1996**, 380, 252-5	50.4	856
27	Effects of chronic intraventricular nerve growth factor treatment on vasoactive intestinal peptide and neuropeptide Y levels in the hippocampal formation and cerebral cortex following fimbrial transections. *Brain Research*, **1994**, 654, 1-7	3.7	6
26	NGF suppression of weight gain in adult female rats correlates with decreased hypothalamic cholecystokinin levels. *Brain Research*, **1994**, 655, 12-6	3.7	18
25	Nerve growth factor pharmacology: application to the treatment of cholinergic neurodegeneration in Alzheimer's disease. *Experimental Neurology*, **1993**, 124, 16-20	5.7	32
24	BDNF and trkB mRNA expression in the hippocampal formation of aging rats. *Neurobiology of Aging* , **1993**, 14, 121-6	5.6	89
23	Protective effects of nerve growth factor and brain-derived neurotrophic factor on basal forebrain cholinergic neurons in adult rats with partial fimbrial transections. *Progress in Brain Research*, **1993**, 98, 257-63	2.9	30
22	Pharmacology of nerve growth factor in the brain. *Advances in Pharmacology*, **1993**, 24, 239-73	5.7	13
21	Effects of chronic basic fibroblast growth factor administration to rats with partial fimbrial transections on presynaptic cholinergic parameters and muscarinic receptors in the hippocampus: comparison with nerve growth factor. *Journal of Neurochemistry*, **1993**, 61, 899-910	6	28
20	Differential alterations of cortical cholinergic and neurotensin markers following ibotenic acid lesions of the nucleus basalis magnocellularis. *Brain Research*, **1993**, 613, 239-46	3.7	9
19	Neurotrophins in the Adult Brain: Effects on Hippocampal Cholinergic Function Following Deafferentation, and Regulation of Their Expression by Pharmacological Agents and Lesions **1993**, 241-253		
18	Neurotrophins in the central nervous system. *Reviews in the Neurosciences*, **1992**, 3, 1-10	4.7	28
17	Therapeutic potential for nerve growth factor in Alzheimer's disease: insights from pharmacological studies using lesioned central cholinergic neurons. *Reviews in the Neurosciences*, **1992**, 3, 109-20	4.7	14
16	BDNF and NGF treatment in lesioned rats: effects on cholinergic function and weight gain. *NeuroReport*, **1992**, 3, 405-8	1.7	139
15	BDNF mRNA expression in the developing rat brain following kainic acid-induced seizure activity. *Neuron*, **1992**, 8, 1127-38	13.9	182

14	Distribution of neurotensin receptors in mammalian brain. What it is telling us about its interactions with other neurotransmitter systems. *Annals of the New York Academy of Sciences*, **1992**, 668, 109-19	6.5	37
13	Neurotrophins and Neurotrophin Receptors in Adult Brain Plasticity. *Journal of Neural Transplantation & Plasticity*, **1992**, 3, 265-266		78
12	Growth factors and lymphokines: modulators of cholinergic neuronal activity. *Canadian Journal of Neurological Sciences*, **1991**, 18, 390-3	1	18
11	Neurotensin regulation of endogenous acetylcholine release from rat striatal slices is independent of dopaminergic tone. *Journal of Neurochemistry*, **1991**, 56, 651-7	6	22
10	Heterogeneous binding of [3H]4-DAMP to muscarinic cholinergic sites in the rat brain: evidence from membrane binding and autoradiographic studies. *Synapse*, **1991**, 9, 165-76	2.4	52
9	Effect of estradiol treatment on beta-endorphin content and release in the female rat hypothalamus. *Brain Research*, **1991**, 554, 198-202	3.7	20
8	Emerging pharmacology of nerve growth factor. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **1991**, 15, 851-60	5.5	8
7	Neurotensin regulation of endogenous acetylcholine release from rat cerebral cortex: effect of quinolinic acid lesions of the basal forebrain. *Journal of Neurochemistry*, **1990**, 55, 1397-403	6	28
6	Chronic estradiol treatment alters central cholinergic function in the female rat: effect on choline acetyltransferase activity, acetylcholine content, and nicotinic autoreceptor function. *Brain Research*, **1990**, 525, 249-55	3.7	42
5	Characterization of [3H]AF-DX 116 binding sites in the rat brain: evidence for heterogeneity of muscarinic-M2 receptor sites. *Synapse*, **1989**, 4, 106-14	2.4	25
4	Binding sites for [3H]AF-DX 116 and effect of AF-DX 116 on endogenous acetylcholine release from rat brain slices. *Brain Research*, **1989**, 496, 285-94	3.7	101
3	Localization of interleukin-2 immunoreactivity and interleukin-2 receptors in the rat brain: interaction with the cholinergic system. *Brain Research*, **1989**, 498, 257-66	3.7	168
2	Growth Factor and Lymphokine Effects on Brain Cholinergic Systems. *Advances in Behavioral Biology*, **1989**, 153-163		2
1	Molecular mechanism of inverse regulation of hepatic alpha-1 and beta-2-adrenergic receptors. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **1985**, 9, 497-502	5.5	3